Biomarin Pharmaceutical Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript
Okay. Welcome, everyone. My name is Gena Wang. I'm smid-cap biotech analyst at the Barclays. It's my great pleasure to introduce our next presenting company, BioMarin. With me on the call at the meeting, we have Hank Fuchs, President of Worldwide R&D; we have Brian Mueller, EVP and Chief Financial Officer. We also have Traci McCarty, VP, Investor Relations.
Okay. So with that, maybe we will start. Hank, I know you won't have a slide presentation, but maybe you can start with a brief introduction about BioMarin, and we will dive right into the Q&A.
Sure. Maybe Brian and I could tag team the brief introduction because the company has quite a lot of strength, both in terms of R&D pipeline advancement -- recent history of R&D pipeline and advancement in new commercial products. So maybe, Brian, do you want to start, kind of give a quick thumbnail on...
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
